India Pharma Outlook Team | Wednesday, 16 July 2025
On Tuesday, Aurobindo Pharma announced that it will produce and distribute cabotegravir, a long-acting injectable HIV therapy, in 133 nations.According to a statement from the firm, the Hyderabad-based pharmaceutical company has been chosen as one of the generic manufacturers under the enlarged voluntary licensing arrangement between ViiV Healthcare and the Medicines Patent Pool (MPP).
According to the statement, the deal enables Aurobindo pharma to produce and distribute the long-acting injectable HIV medication in 133 nations, including a number of low- and middle-income markets. In addition to its previous usage for HIV prevention solely, long-acting cabotegravir (CAB LA) is now included in this update for HIV treatment. The treatment offers an alternative to daily pills, allowing patients to receive just one injection every one or two months.
"We are privileged to be part of the sub-license expansion from MPP and ViiV to develop, manufacture, and distribute generic CAB LA in select markets for the treatment of HIV-1, in addition to the voluntary licence for PrEP," Aurobindo Pharma vice Chairman & Managing Director K Nithyananda Reddy said. This is a significant and timely step towards increasing access to advanced long-acting treatment in LMICs, he added.
Also Read: Baxdrostat Phase III Trial Significantly Lowers Blood Pressure in Hypertension
It was stated by Aurobindo that its global supply capabilities are committed to being leveraged to make this vital combination long-acting injection therapy widely available and affordable. The inclusion of the private market in royalty-bearing countries by ViiV and MPP is considered a critical step toward expanding access across both public and private sectors, it was added.
